Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL19100909 | 0.99 | TLR2 (0.54) | TLR2KMT2ACASP3EPHX2 | |
| Bromide SCHEMBL15640173 | 0.90 | KMT2A (0.53) | TLR2KMT2ACASP3EPHX2 | |
| Hydrochloric Acid SCHEMBL2524994 | 0.90 | KMT2A (0.53) | TLR2KMT2ACASP3EPHX2 | |
| SCHEMBL8064281 | 0.87 | TLR2 (0.53) | TLR2KMT2ACASP3EPHX2 | |
| SCHEMBL17193169 | 0.87 | TLR2 (0.53) | TLR2KMT2ACASP3EPHX2 | |
| SCHEMBL10074916 | 0.87 | TLR2 (0.53) | TLR2KMT2ACASP3EPHX2 | |
| SCHEMBL2190711 | 0.86 | KMT2A (0.47) | TLR2KMT2ACASP3EPHX2 | |
| SCHEMBL8453044 | 0.86 | KMT2A (0.56) | TLR2KMT2ACASP3EPHX2 | |
| SCHEMBL17193149 | 0.86 | TLR2 (0.52) | TLR2KMT2ACASP3EPHX2 | |
| Hydrochloric Acid SCHEMBL3162296 | 0.85 | KMT2A (0.55) | TLR2KMT2ACASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | UCL BUSINESS PLC (GB) | 2012-06-21 | — | — | US | disclosed |
| EP-2453925-A2 | CYCLOSPORIN CONJUGATES | UCL Business PLC (GB) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011010084-A2 | CYCLOSPORIN CONJUGATES | UCL BUSINES PLC (GB) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157385-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | TLR2 2328/4885KMT2A 3065/4885CASP3 567/4885 |
| US-20140357569-A1 | CYCLOSPORIN CONJUGATES | CYP11B1, SHMT2, MRM1 | TLR2 2208/4885KMT2A 3078/4885CASP3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.